Residency · Residency · Psychiatry
ADHD Across the Lifespan
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that impair functioning across multiple domains. Once considered exclusively a childhood condition, ADHD is now recognized as persisting into adulthood in approximately 50-65% of cases. Understanding its evolving presentation across the lifespan is essential for accurate diagnosis and effective management.
Epidemiology
Prevalence in children: approximately 5-7% worldwide. Prevalence in adults: approximately 2.5-4%. Male-to-female ratio in childhood approximately 2:1; ratio narrows in adulthood to approximately 1.5:1. Females are frequently underdiagnosed due to predominantly inattentive presentations with less disruptive behavior.
DSM-5 Diagnostic Criteria
Six or more symptoms of inattention and/or hyperactivity-impulsivity (five for adults aged 17+) Symptoms present before age 12. Symptoms present in two or more settings. Clear evidence of functional impairment. Three presentations: predominantly inattentive, predominantly hyperactive-impulsive, combined.
Developmental Trajectory
Childhood
Hyperactivity and impulsivity are often the most prominent features. Difficulty following instructions, staying seated, waiting turns. Academic underperformance relative to cognitive ability. Peer relationship difficulties and behavioral problems.
Adolescence
Overt hyperactivity may diminish; replaced by inner restlessness. Executive function deficits become more impairing: poor time management, disorganization, procrastination. Increased risk of substance experimentation, risky driving, academic failure. Emotional dysregulation becomes more apparent.
Adulthood
Inattention symptoms tend to persist more than hyperactivity. Occupational difficulties: missed deadlines, job changes, underemployment. Relationship instability and difficulty with household management. High comorbidity with anxiety, depression, and substance use disorders.
Neurobiology
Prefrontal cortex hypofunction: deficits in executive function, working memory, and inhibitory control. Dysregulation of catecholamine circuits (dopamine and norepinephrine) Structural differences: reduced volume in prefrontal cortex, caudate nucleus, and cerebellum. Delayed cortical maturation, particularly in prefrontal regions (approximately 3-year delay in peak cortical thickness) Heritability estimated at 70-80%.
Assessment
Clinical Interview
Detailed developmental history with corroboration from parents, teachers, or partners. Assess functioning across academic, occupational, and social domains. Screen for comorbid conditions: mood disorders, anxiety, learning disabilities, substance use.
Rating Scales
Conners Rating Scales (child and adult versions) Vanderbilt Assessment Scales (pediatric) Adult ADHD Self-Report Scale (ASRS). WURS (Wender Utah Rating Scale) for retrospective childhood symptom assessment.
Neuropsychological Testing
Not required for diagnosis but helpful in complex or ambiguous cases. Continuous performance tests (CPT) have limited sensitivity and specificity. Most useful for identifying comorbid learning disabilities.
Treatment
Pharmacotherapy
| Class | Agent | Mechanism | Onset | Duration | Key Considerations |
|---|---|---|---|---|---|
| Stimulant | Methylphenidate IR | DAT/NET blockade | 20-30 min | 3-4 hr | Multiple daily doses needed |
| Stimulant | Methylphenidate ER (Concerta, Ritalin LA) | DAT/NET blockade | 30-60 min | 8-12 hr | Various release mechanisms |
| Stimulant | Mixed amphetamine salts (Adderall) | DA/NE release + reuptake inhibition | 30-60 min | 4-6 hr (IR), 10-12 hr (XR) | Higher potency; more abuse potential |
| Stimulant | Lisdexamfetamine (Vyvanse) | Prodrug of d-amphetamine | 1-2 hr | 10-14 hr | Lower abuse potential (prodrug design) |
| Non-stimulant | Atomoxetine | Selective NET inhibitor | 2-4 weeks | 24 hr | No abuse potential; may help anxiety |
| Non-stimulant | Guanfacine XR | Alpha-2A agonist | 1-2 weeks | 24 hr | Reduces hyperactivity/impulsivity; sedating |
| Non-stimulant | Viloxazine ER | NE reuptake inhibitor + 5-HT modulation | 1-2 weeks | 24 hr | FDA-approved 2021; ages 6+ |
| Non-stimulant | Clonidine XR | Alpha-2 agonist | 1-2 weeks | 12-24 hr | Adjunctive; sedation, hypotension |
Stimulants are first-line: methylphenidate and amphetamine formulations. Effect sizes are among the largest in psychiatry (approximately 0.8-1.0) Non-stimulant options: atomoxetine, guanfacine extended-release, viloxazine, clonidine extended-release. In adults, monitor for cardiovascular effects; obtain baseline vitals and consider ECG if risk factors present.
Psychosocial Interventions
Behavioral parent training is first-line for preschool-age children. Classroom accommodations and school-based interventions. CBT adapted for adult ADHD: targets executive function deficits, time management, organization. Psychoeducation for patients and families.
Multimodal Treatment
The MTA Study demonstrated that combined medication and behavioral therapy provides the best outcomes for most children. Medication management alone was superior to behavioral treatment alone for core ADHD symptoms. Behavioral strategies are essential for addressing functional impairments that medication does not fully resolve.
Key Clinical Pearls
ADHD is not a diagnosis of childhood; it requires lifespan awareness and longitudinal follow-up. Stimulant diversion and misuse are genuine concerns; use prescription monitoring programs and consider non-stimulant options when risk is high. Emotional dysregulation is a core feature of ADHD, though not included in DSM criteria. Late diagnosis in women and girls is common; suspect ADHD when anxiety or depression treatment has been only partially effective. Treatment of ADHD in individuals with comorbid substance use disorders reduces relapse risk.
References
- Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789-818.
- MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1073-1086.
- Kooij JJS, Bijlenga D, Salerno L, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14-34.
- Shaw P, Eckstrand K, Sharp W, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA. 2007;104(49):19649-19654.